NORTHERN NEW JERSEY COMMUNITY CLINICAL ONCOLOGY PROGRAM

北方新泽西社区临床肿瘤学项目（NNJ-CCOP） 提供国家合作临床试验， 在北方新泽西人口最多的9个县， 与纽约接壤。在这种背景下，哈肯萨克医疗中心 (HMC)每年诊断出1500名新的癌症患者， 过去的五年里在成人和成人中，患者数量显著增加 儿科肿瘤学数量增加， 扩大医疗中心的肿瘤学设施和项目 形成一个完美的背景，增加研究贡献期间， 未来5年。 NNJ-CCOP汇集了一组的力量和资源， 多学科研究者合作开展研究 POG、ECOG、NSABP和URCC。调查人员29人，其中13人 两个以医院为基础的私人执业团体的血液学家/肿瘤学家 为所有年龄段的患者提供服务。他们在这两方面的成就都是上级的 研究的科学性以及临床试验的收益。 在未来五年，总体目标是降低癌症发病率， 发病率和死亡率，加速新开发的 癌症预防，早期发现，治疗，病人管理， 康复和持续护理技术，以广泛的社区 应用程序.通过精心设计，该计划将尽可能多地集中，如果不是这样的话。 更多的关注和资源用于癌症控制研究，而不是治疗 治疗和癌症控制的这两个目标是一个现成的 与患者人群匹配，符合NNJ-CCOP利益， 能力的 NNJ-CCOP的近期目标是继续我们的强劲增长 治疗试验的比率;通过提供 我们的治疗方案菜单上的其他研究;以促进更广泛的 社区参与，包括少数群体和得不到充分服务的群体 NCI批准的治疗和癌症控制研究中的人群; 培养与初级保健医生和其他专家的联系， 可能有助于癌症控制倡议;并改善癌症控制 数据管理能力，包括使用一系列资源， 确定癌症控制研究项目的潜在候选人。的 前列腺癌预防试验（PCPT）的开展是一项主要的 objective.对于本研究，CCOP是以下2家获批研究中心之一： 新泽西。 总之，NNJ-CCOP的业绩记录表明， 管理复杂的临床研究和癌症控制活动， 产生最高质量的数据。NNJ-CCOP拥有设施， 训练有素的专业人员，以支持癌症治疗和 癌症控制试验CCOP人员配置模式、礼宾管理 程序、患者/参与者管理方法、质量控制 机构，药房控制机制，IRB结构和联络都是 以支持当前和未来的治疗和 癌症控制活动。 在1994年至1999年期间，将为2200多个议定书条目提供资料。 CCOP临床试验：665项进入治疗试验，1560项进入 癌症控制试验每年153.5治疗学分和131.5 癌症控制信贷。

The Northern New Jersey Community Clinical Oncology Program (NNJ-CCOP) provides access to national cooperative clinical trials for over 4.9 million people in the 9 most populous counties in northern New Jersey and bordering New York. Against this background, the Hackensack Medical Center (HMC) diagnoses 1500 new cancer patients per year, an increase of 30% in the last five years. Patient volumes have increased markedly in both Adult and Pediatric Oncology. Increased volume together with the growth and expansion of the oncology facilities and programs at the Medical Center form a perfect backdrop for increased research contributions during the next 5 years. The NNJ-CCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from POG, ECOG, NSABP, and URCC. The investigators number 29 including 13 hematologists/oncologists in two hospital-based private practice groups serving patients of all ages. Their accomplishments are superior in both the science of the research as well as accrual to clinical trials. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus as much, if not more, attention and resources on cancer control research than treatment These twin objectives of both treatment and cancer control are a ready match for the patient population and fit within NNJ-CCOP interests and capabilities. The immediate goals of the NNJ-CCOP are to continue our strong accrual rate to treatment trials; to increase research activity by offering additional studies on our treatment protocol menu; to facilitate wider community participation, including minority groups and underserved populations in treatment and cancer control research approved by NCl; to cultivate contacts with primary care physicians and other specialists who may contribute to cancer control initiatives; and to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The conduct of the Prostate Cancer Prevention Trial (PCPT) is a primary objective. For this study, the CCOP is 1 of 2 approved Study Centers in New Jersey. In summary, the track record of the NNJ-CCOP demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The NNJ-CCOP has the facilities and well-trained professional personnel to support both cancer treatment and cancer control trials. The CCOP staffing pattern, protocol management procedures, patient / participant management approaches, quality control mechanisms, pharmacy control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Between 1994 and 1999, over 2200 protocol entries will be contributed to CCOP clinical trials: 665 entries to treatment trials and 1560 entries to cancer control trials per year for 153.5 treatment credits and 131.5 cancer control credits.